Pediatric Hodgkin Lymphoma Treatment Trial With Low Cumulative Doses of Chemotherapy Agents and Reduced Radiation.

PHASE4RecruitingINTERVENTIONAL
Enrollment

500

Participants

Timeline

Start Date

October 6, 2017

Primary Completion Date

October 31, 2027

Study Completion Date

October 31, 2032

Conditions
Pediatric Hodgkin's Disease
Interventions
RADIATION

No radiotherapy if CR at the end of chemotherapy.

Adapted chemotherapy without radiotherapy

DRUG

Low risk with complete early response after two cycles of ABVD chemotherapy schedule. Only one more ABVD course is delivered.

Low risk with complete early response after two cycles of ABVD chemotherapy schedule. Only one more ABVD course is delivered.

DRUG

Low risk with partial remisssion after 4 cycles of ABVD chemotherapy schedule. Two ESHAP courses are delivered.

Low risk with partial remission at early response assessment after two cycles of ABVD chemotherpay schedule. Two ABVD courses are delivered.

RADIATION

IN 30Gy RT in case of PR at the end of chemotherapy

Low risk with partial remisssion after 4 cycles of ABVD and 2 ESHAP courses: IN 30Gy RT

DRUG

Intermediate risk with complete early response after two cycles of ABVD chemotherapy schedule. Three more ABVD courses are delivered.

Intermediate risk with complete early response after two cycles of ABVD chemotherapy schedule. Three more ABVD courses are delivered.

DRUG

Intermediate risk with partial remission after two cycles of ABVD chemotherapy schedule. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.

Intermediate risk with partial remission after two cycles of ABVD chemotherapy schedule. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.

DRUG

High risk with complete early response after 1 ABVD and 1 ESHAP courses. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.

High risk with complete early response after 1 ABVD and 1 ESHAP courses. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.

DRUG

High risk with partial remission after 1 ABVD and 1 ESHAP courses. Six more chemotherapy courses are delivered alternating ESHAP and ABVD.

High risk with partial remission after 1 ABVD and 1 ESHAP courses. Six more chemotherapy courses are delivered alternating ESHAP and ABVD.

DRUG

Low risk with partial remission at early response assessment after two cycles of ABVD chemotherpay schedule. Two ABVD courses are delivered.

Low risk with partial remission at early response assessment after two cycles of ABVD chemotherpay schedule. Two ABVD courses are delivered.

Trial Locations (1)

C1245AAL

RECRUITING

Hospital JP Garrahan, Buenos Aires

All Listed Sponsors
lead

Hospital JP Garrahan

OTHER_GOV